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Background: Anemia is a serious and highly prevalent co-morbidity in chronic heart failure (HF) patients. Its
inﬂuence on health-related quality of life (HR-QoL) has rarely been studied, and no data is available regard-
ing the role it plays in hospitalized HF patients.
Methods: Baseline data from the COACH study (Coordinating study evaluating Outcomes of Advising and
Counselling in Heart Failure) were used. HR-QoL was assessed by means of generic and disease-speciﬁc ques-
tionnaires. Analyses were performed using ANOVA and ANCOVA, with covariates of age, gender, eGFR, diabe-
tes, and NYHA class.
Results: In total, 1013 hospitalized patients with a mean age of 71 (SD 11) years were included; 70% of these
patients had no anemia (n=712), 14% had mild anemia (n=141), and 16% had moderate-to-severe anemia
(n=160). Independent associations were found between anemia and physical functioning (p=0.019), ane-
mia and role limitations due to physical functioning (p=0.002), anemia and general health (p=0.024), and
anemia and global well-being (p=0.003).
Conclusion: In addition to the burden of HF itself, anemia is an important factor which inﬂuences HR-QoL in
hospitalized HF patients, and one that is most pronounced in the domain related to physical functioning and
general health.© 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Relief of symptoms and improvement in health-related quality of
life (HR-QoL) are recognized as important objectives in the treatment
of heart failure (HF) in international HF guidelines [1]. However, de-
spite the improvements in medical treatment resulting in prolonged
survival and reduction of hospitalizations, HF patients still have an
impaired HR-QoL [2]. HR-QoL in HF patients is seriously reduced com-
pared to a normative population in the community [2], as well as
compared to patients with other chronic diseases [3]. Health status
measurements such as HR-QoL quantify the extent to which a patient
is impaired by the disease [4]. A poor health status is a signiﬁcant pre-
dictor of adverse prognosis in patients with chronic HF [5]; therefore,
reduction of HF symptoms and improvement in HR-QoL should be an
important treatment goal for clinicians and other health-care profes-
sionals. In clinical trials, there is also an increasing interest in measur-
ing patient-reported outcomes such as HR-QoL, since this has recently
been recommended by the US Food and Drug Administration [6].lands Heart Foundation as part
.
n, University Medical Center
01, 9700 RB Groningen, The
e Elsevier OA license.Anemia is a serious co-morbidity in patients with chronic HF and
is prevalent in more than one-third of these patients [7]. Anemia
may cause a wide range of symptoms and impairments which corre-
spond to the symptoms of HF such as dizziness, tachycardia, and dys-
pnea [1]. The severity of the symptoms depends on the degree of
anemia, other co-morbidities, compensatory mechanisms, and the
physiological status of the patient. Although the inﬂuence that ane-
mia has on HF patients in terms of HR-QoL has rarely been studied, in-
tervention trials to correct anemia have already used HR-QoL as an
effect parameter [8–11]. To date, only one study has examined the di-
rect relationship between HR-QoL and anemia in a population of 826
HF-stable outpatients with a mean age of 64 years [12]. To our knowl-
edge, there are no data available regarding the role it plays in hospi-
talized HF patients. The aim of the present study is to further assess
the relationship between HR-QoL and anemia in hospitalized HF pa-
tients. The following research questions will be addressed in this
study: Is there an independent association between HR-QoL and ane-
mia in hospitalized HF patients? Is this association present in speciﬁc
aspects of HR-QoL?
2. Methods
2.1. Participants
Baseline data from the COACH study (Coordinating study evaluating Outcomes of
Advising and Counselling in Heart Failure) were used for this study. The COACH
152 IH. Kraai et al. / International Journal of Cardiology 161 (2012) 151–155study was a multicenter, randomized controlled trial designed to compare the effects
of basic support and intensive support in HF patients, using a control group receiving
usual care [13]. Details on the design of the COACH study have been published else-
where [14]. In short, 1023 patients from seventeen hospitals in the Netherlands were
included in the study from October 2002 to February 2005. Patients were included dur-
ing admission to the hospital with symptoms of HF and NYHA II–IV. The HF diagnosis
was made on the basis of a combination of typical signs and symptoms, for which hos-
pitalization was considered necessary, including the need for intravenously adminis-
tered medication. Other enrolment criteria were 18 years of age or older and having
evidence of structural underlying heart disease. Patients with impaired left ventricular
ejection fraction (LVEF) and those with preserved LVEF could also be included. Patients
were excluded if they were unable to complete data collection forms, had undergone
invasive intervention within the last 6 months or had one planned for the ensuing
3 months, or were in ongoing evaluation for heart transplantation. During hospitaliza-
tion, patients were randomized to one of the following groups: basic support, intensive
support, or control group. Our investigation conforms to the principles outlined in the
Declaration of Helsinki. The medical ethics committee approved the study protocol,
and all the enrolled patients provided their written informed consent. The authors of
this manuscript have certiﬁed that they are in compliance with the Principles of Ethical
Publishing in the International Journal of Cardiology [15].
2.2. Measurements
2.2.1. HR-QoL
HR-QoL was assessed using three instruments: two generic (RAND 36-item Health
Survey 1.0 and Cantril's Ladder of Life) and one disease-speciﬁc instrument, the Minne-
sota Living with Heart Failure Questionnaire (MLHFQ). In general, disease-speciﬁc
questionnaires are used for patients with a speciﬁc health condition, while generic in-
struments are used in patients with various health conditions [16,17]. Generic instru-
ments are not affected in terms of their validity, reliability, and responsiveness if a
patient has co-morbidities which manifest similar effects as a primary disease [18]. Ge-
neric HR-QoL can be inﬂuenced by nonmedical phenomena such as employment and
family relationships [16]. Therefore we used a global QoL instrument (Cantril's Ladder
of Life) in addition to a generic HR-QoL instrument (RAND 36-item Health Survey 1.0)
[19].
The RAND 36-item Health Survey 1.0 consists of eight domains: physical function-
ing, social functioning, role limitations (physical problems), role limitations (emotional
problems), mental health, vitality, bodily pain, and general health perception. For each
domain, scores range from 0 (poorest health) to 100 (best health). Higher scores re-
ﬂect better HR-QoL. The RAND 36-item Health Survey 1.0 includes the same items as
those in the SF-36; however, the scoring algorithm is different compared to the SF-
36. Therefore the RAND 36-item Health Survey 1.0 does not have component summary
scores [20]. Moreover, unlike the SF-36, the RAND 36-item Health Survey 1.0 does not
have norm scores available for comparison. It has, however, previously been used in aTable 1
Characteristics of the study population.
Characteristics All patients
(n=1013)
Non-anemic
(n=712)
Demographics
Age yrs 71 (±11) 70 (±11)
Male % (N) 62% (632) 62% (439)
Clinical variables
NYHA % (N)
II 51% (506) 53% (369)
III 46% (458) 44% (312)
IV 3% (34) 3% (21)
LVEF 34 (±14) 33 (±14)
eGFR (mL/min/1.73 m2) 56 (±20) 59 (±19)
Hb (mmol/L) 8.3 (±1.1) 8.9 (±0.8)
BNP (ng/L) 680 (±729) 623 (±675)
Discharge medication % (N)
ACE/ARB 83% (838) 87% (617)
β-Blockers 66% (670) 67% (479)
Diuretics 96% (970) 96% (682)
Medical history % (N)
Diabetes 28% (285) 25% (175)
COPD 26% (267) 25% (176)
Stroke 10% (105) 8% (60)
Hypertension 43% (436) 42% (299)
Note: Characteristics described as means (±SD); p: between anemic groups; H
Hb≥8.0 mmol/L; Mild anemic female: 6.8 mmol/L≤Hbb7.5 mmol/L; Mild anem
Hbb6.8 mmol/L; Moderate-to-severe anemicmale: Hbb7.5 mmol/L; NYHA: New
ed glomerular ﬁltration rate; BNP: brain natriuretic peptide; ACE/ARB: angiotensin
monary disease.Dutch population and was found to have good psychometric properties [21,22]. Gener-
ally speaking, a difference of 5 points on the domain scores is considered to be clinical-
ly relevant. The Cantril's Ladder of Life assesses a patient's global well-being on a scale
between zero, indicating the poorest, and 10, indicating the best well-being, and has
been used in HF research before [23,24]. The MLHFQ is a widely used disease-speciﬁc
questionnaire in HF research [19,25] that has good psychometric properties [25]. The
MLHFQ has a total score ranging between zero and a maximum of 105, and consists
of two domains, a physical component and an emotional component with, respective-
ly, 40 and 25 as maximum possible scores. Lower scores on the MLHFQ reﬂect better
HR-QoL [26].2.2.2. Clinical measurements
Anemia was deﬁned for adult men and women according to the deﬁnition of the
World Health Organization (WHO) as a hemoglobin (Hb) level being, either below
8.0 mmol/L or below 7.5 mmol/L, respectively [27]. To examine the association be-
tween the severity of the anemia and HR-QoL, subgroups of anemic patients were cre-
ated. To create suitable groups for comparison in the present study, we combined data
from patients with severe anemia and moderate anemia into one group, denoted as the
moderate-to-severe anemia group. Mild anemia was deﬁned for male and female pa-
tients as an Hb level below 8.0 mmol/L and 7.5 mmol/L, respectively. Moderate-to-
severe anemia was deﬁned as an Hb level lower than 7.5 mmol/L in male patients,
and an Hb level lower than 6.8 mmol/L in female patients [28].
Demographic and clinical data were collected from patient interviews and from
patients' medical charts at baseline, except for LVEF, which was measured close to ad-
mission and at a maximum of one year before or after.2.3. Statistical analysis
Patient characteristics and clinical and HR-QoL outcomes were described using
means (±SD) for continuous variables and using percentages and numbers for cate-
gorical variables. Continuous variables were tested using one-way analysis of variance
(ANOVA), and categorical variables using the Chi square test. Welch F tests were per-
formed if the homogeneity of variance was violated according to Levine's test. Analysis
of covariance (ANCOVA) was used to assess an independent association between anemia
and HR-QoL, along with a correction for variables known to inﬂuence Hb levels and HR-
QoL such as age [29], gender [27,30], diabetes [2], eGFR [31], and NYHA classiﬁcation
[32]. Severity of anemia (no anemia, mild anemia, and moderate-to-severe anemia) was
the factor variable, while HR-QoL was the dependent variable. Comparisons between
the different anemia groups were performed using post hoc analyses with correction for
multiple comparisons using Bonferroni. A regression analysis was performed to deter-
mine the contribution of anemia to the physical functioning domains. Statistical analyses
were performed using SPSS version 18.0.3 for Windows.Mild-anemic
(n=141)
Moderate-to-severe anemic
(n=160)
p Value
72 (±11) 73 (±11) 0.001
56% (79) 71% (114) 0.019
46% (65) 46% (72)
51% (72) 48% (74) 0.088
2% (3) 6% (10)
36 (±15) 36 (±15) 0.011
50 (±21) 48 (±23) b0.001
7.5 (±0.3) 6.6 (±0.5) b0.001
734 (±796) 887 (±856) 0.001
76% (107) 71% (114) b0.001
68% (96) 59% (95) 0.141
97% (137) 94% (151) 0.487
31% (44) 41% (66) b0.001
29% (41) 31% (50) 0.174
11% (15) 19% (30) 0.001
55% (78) 37% (59) 0.003
b: hemoglobin; Non-anemic female: Hb≥7.5 mmol/L; Non-anemic male:
ic male: 7.5 mmol/L≤Hbb8.0 mmol/L; Moderate-to-severe anemic female:
York Heart Association; LVEF: left ventricular ejection fraction; eGFR: estimat-
-converting enzyme/angiotensin II inhibitor; COPD: chronic obstructive pul-
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3.1. Study population
Patients were included in the current study if baseline levels of Hb
were available; as a result of this, 1013 patients were included. Patients
had amean age of 71 (±11) years, while 62% of the patients weremale.
Most patients were classiﬁed as NYHA III–IV upon admission; while on
discharge most were NYHA class II (51%) or III (46%). Co-morbidities
were present: 28% of thepatients had diabetes, 26% had chronic obstruc-
tive pulmonary disease (COPD), 10% have had a stroke and 43% had hy-
pertension (Table 1). On the basis of the WHO deﬁnition, 30% were
anemic, 14% hadmild anemia, and 16% hadmoderate-to-severe anemia.
Baseline characteristics differed signiﬁcantly across the anemic groups.
The severity of anemia was associated with higher age (p=0.001),
higher LVEF (p=0.011), lower eGFR levels (pb0.001), male gender
(p=0.019), the use of angiotensin-converting enzyme or angiotensin
II inhibitor (pb0.001), higher prevalence of the co-morbidities of diabe-
tes (pb0.001), and stroke (p=0.001). A non-signiﬁcant associationwas
found for NYHA classiﬁcation and severity of anemia (Table 1).
3.2. Association between HR-QoL and anemia
For the RAND 36-item Health Survey 1.0, univariate analyses
(Table 2) indicated signiﬁcant associations between anemia and the
ﬁve domains of the survey: physical functioning (pb0.001), role lim-
itation physical (pb0.001), role limitation emotional (p=0.028),
bodily pain (p=0.038), and general health (p=0.002). Three do-
mains remained signiﬁcant in the multivariate analyses: physical
functioning (p=0.019), role limitation physical (p=0.002), and gen-
eral health (p=0.024). In terms of the contribution of anemia to HR-
QoL for the domains physical functioning and role limitation physical,
anemia showed for physical functioning the lowest standardized beta
coefﬁcient (−0.076) when compared to NYHA classiﬁcation (−0.29),
gender (−0.11), renal function (0.10), age (−0.09) and the presence
of diabetes (−0.09). For role limitation physical these ﬁgures were
less attenuated; anemia (−0.11), NYHA classiﬁcation (−0.17), gen-
der (−0.03), renal function (0.001), age (0.04) and the presence of
diabetes (−0.04). Post hoc analyses (Fig. 1) indicated an independent
signiﬁcant association between non-anemic versus mild anemic pa-
tients (p=0.019), and between non-anemic versus moderate-to-
severe anemic patients (p=0.026) in the domain of role limitationTable 2
Univariate and multivariate analyses of the association between HR-QoL and
Characteristics Non-anemic
(n=712)
Mild anemic
(n=141)
RAND 36-item Health Survey
Physical functioning 37 (±27) 29 (±23)
Social functioning 54 (±31) 53 (±31)
Role limitation physical 21 (±35) 11 (±27)
Role limitation emotional 54 (±45) 48 (±45)
Mental health 66 (±23) 65 (±20)
Vitality 40 (±23) 40 (±21)
Bodily pain 66 (±33) 61 (±31)
General health 45 (±19) 41 (±17)
MLHFQ
Total 43 (±22) 46 (±20)
Physical component 22 (±10) 24 (±9)
Emotional component 7 (±6) 7 (±6)
Ladder of Life 6.4 (±1.9) 6.2 (±1.8)
Note: Characteristics described as mean (±SD); Hb: hemoglobin; Non-anemic
mic female: 6.8 mmol/L≤Hbb7.5 mmol/L; Mild anemic male: 7.5 mmol/L≤
Moderate-to-severe anemic male: Hbb7.5 mmol/L.
⁎ p univariate association between HR-QoL and anemia severity.
⁎⁎ p multivariate association between HR-QoL and anemia severity with covphysical. For the domain of general health, signiﬁcant associations were
found between non-anemic versus moderate-to-severe anemic patients
(p=0.040). A non-signiﬁcant association between non-anemic versus
mild anemic patients for the domain of physical functioning (p=0.059)
was found.
Using Cantril's Ladder of Life, a signiﬁcant univariate association was
found between anemia and global well-being (p=0.003). This associa-
tion remained signiﬁcant in themultivariate analyses (p=0.003), specif-
ically between non-anemic versus moderate-to-severe anemic patients
(p=0.002) (Fig. 2).
For MLHFQ, neither the total score, nor the physical and emotional
components were associated with anemia.
4. Discussion
This is the ﬁrst study to report on a signiﬁcant independent associa-
tion between HR-QoL and anemia in patients hospitalized for HF. The
current study provides further support for the relationship between
HR-QoL and anemia in HF patients. Although the association between
HR-QoL and anemia was reported in other diseases [33,34], in HF
patients only one study reported on this direct relationship in a stable
outpatient population with a mean age of 64 years, independent of
functional class, ejection fraction, gender, and age [12]. The present
study adds to this by showing that this independent association is also
present in hospitalized HF patients. In these patients, hospitalized be-
cause of severe HF symptoms which often result in a severely impaired
HR-QoL [2], we still found an independent association between anemia
and HR-QoL.
The present study is also the ﬁrst to use both generic and disease-
speciﬁc questionnaires to assess the association between HR-QoL and
anemia. In using those questionnaires, we considered HR-QoL in pa-
tients in terms of its speciﬁc relationship to their HF and in terms of a
general, broader concept, unrelated to any speciﬁc disease. Independent
associations were only found between generic HR-QoL and anemia,
whichwould indicate that HF patients with anemia have additional dif-
ﬁculties on top of their HF symptoms; these difﬁculties cannot be
detected by disease-speciﬁc questionnaires alone. Another explanation
could be that the MLHFQ was not sensitive enough in this population
because of the small sample sizes in the anemia groups [35]. Moreover,
the MLHFQ is not speciﬁcally designed for use in acute HF, though it is
very frequently used in HF trials to study patients with chronic HF.
The most pronounced associations between HR-QoL and anemia wereanemic and non-anemic patients.
Moderate-to-severe anemic
(n=160)
⁎p ⁎⁎p
29 (±23) b0.001 0.019
48 (±30) 0.056
12 (±28) b0.001 0.002
43 (±45) 0.028 0.146
65 (±24) 0.949
37 (±22) 0.319
59 (±34) 0.038 0.142
39 (±18) 0.002 0.024
45 (±21) 0.104
24 (±9) 0.138
7 (±6) 0.989
5.8 (±2.0) 0.003 0.003
female: Hb≥7.5 mmol/L; Non-anemic male: Hb≥8.0 mmol/L; Mild ane-
Hbb8.0 mmol/L; Moderate-to-severe anemic female: Hbb6.8 mmol/L;
ariates age, gender, NYHA classiﬁcation, diabetes, and eGFR level.
Fig. 1. Post hoc analyses of health-related quality of life measured using the RAND 36-
item Health Survey in heart failure patients without anemia, and in those with mild
and moderate-to-severe anemia. Lines indicate a signiﬁcant difference (pb0.05) be-
tween the group with correction for age, gender, NYHA classiﬁcation, diabetes, and
eGFR level. (PF = physical functioning; SF = social functioning; RF = role limitations
due to physical functioning; RE= role limitations due to emotional functioning; MH=
mental health; VT = vitality; BP = bodily pain, GHP = general health perception).
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physical functioning. Both domains reﬂect limitations in terms of per-
forming daily activities, such as climbing stairs, bathing or dressing, or
carrying groceries, which are due to physical health problems [21,22].
These daily activities are particularly important for older adults in
maintaining or increasing their quality of life [36]. Moreover, physical
activity in terms of exercise and the performance of daily activities is
recommended for HFpatients [1,37]; this is an established life-style rec-
ommendation [37,38] for improving HR-QoL [37]. Furthermore, inde-
pendent associations were found for general health and global well-
being, which reﬂects the fact that HF patients with anemia have a
lower opinion of their health than do HF patients without anemia.
This independent association remains if we correct for other co-
morbidities such as stroke and hypertension. This is in accord with the
literature: HR-QoL declines with any increasing burden of co-
morbidity in cardiac patients [2,39]. In general, older people with ane-
mia experience a decline in functional status and physical strength as
compared to non-anemic elderly [40]. In contrast to the study by
Thein and colleagues, in which anemia was associated with depressive
symptoms [40], we found no relationship between anemia and the
mental aspects of HR-QoL. We also did not ﬁnd any signiﬁcant associa-
tion between anemia and the HR-QoL domain of vitality, which reﬂects
feelings of energy and tiredness [21,22]. Tiredness and lack of energy
are symptoms of both anemia and HF, which may explain why no sig-
niﬁcant association was found for this domain.
In addition to the substantial risk of adverse events and death in
anemic HF patients [41], these patients also seem at risk of a decline
in their HR-QoL. Although our study had a cross-sectional designFig. 2. Post hoc analyses of health-related quality of lifemeasured using Cantril's Ladder of
Life in heart failure patientswithout anemia, and in thosewithmild,moderate, and severe
anemia. Line indicates a signiﬁcant difference (pb0.05) between the group with correc-
tion for age, gender, NYHA classiﬁcation, diabetes, and eGFR level.which precludes conclusions as to causality, our ﬁndings suggest
that speciﬁc treatment for anemia should be considered because ef-
fective treatment may improve HR-QoL in these HF patients. Al-
though the best treatment for anemia in HF patients is still open to
debate [42], the ﬁrst randomized clinical trials suggest that treating
anemia improves exercise tolerance, reduces symptoms, and im-
proves HR-QoL [11,41].
One limitation of our study is that we performed post hoc analyses
that assessed the association between HR-QoL and anemia using
baseline data from the COACH study; this study was originally
designed to determine the effectiveness of two interventions (basic
support versus intensive support) as compared to “care as usual” in
HF patients with the following primary endpoint: the composite of
HF hospitalization or death from any cause and the number of unfa-
vorable days. Another limitation is that data from clinical trials are
known to present difﬁculties in terms of generalizability. However,
we believe that this is a sample that reasonably represents the clinical
sample of HF patients in general [2] in view of the mean age of
71 years and the distribution of male patients in the study population.
5. Conclusion
The most important ﬁnding of this study is that HR-QoL has been
shown to be independently associated with anemia in hospitalized HF
patients in terms of global well-being, general health, physical func-
tioning, and limitations due to physical functioning. HR-QoL was
found to be particularly lower in patients with severe-to-moderate
anemia. The association between HR-QoL and (severe) anemia in HF
patients is remarkable, and might serve as a possible mechanism for
improving HR-QoL in anemic HF patients. More research into this as-
sociation is needed.
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